Results 221 to 230 of about 4,904,701 (256)

24S-Hydroxycholesterol: A potential brain-derived biomarker of Huntington’s Disease

Ali Asgari M, Langbehn DR, Skibinski DOF, Lee R, Griffiths WJ, Wang Y.   +5 more
europepmc   +1 more source

Advancing Marine Mammal Conservation Through Omics Tools and Integration of Indigenous Ecological Knowledge

Molecular Ecology, Volume 35, Issue 19, October 2026.
ABSTRACT Conservation of biodiversity is a global priority as human‐driven pressures continue to intensify and alter ecosystems worldwide. Marine mammals are vulnerable species, facing numerous escalating anthropogenic threats. Here, we evaluate how, as omics technologies become more accessible and affordable, established and emerging tools are ...
Isabella M. Reeves, Gabrielle Genty, Alana Alexander, Diana Aguilar‐Gómez, Kerstin Bilgmann, Ane Liv Berthelsen, Arial M. Brewer, Emma L. Carroll, Grace A. Day, Eda M. Dönmez, Franca Eichenberger, Fabricio Furni, Joseph I. Hoffman, Steven Holmes, Keith M. Hernandez, Karen K. Martien, Svenja M. Marfurt, Morgan L. McCarthy, Phillip A. Morin, Mariana F. Nery, Sergio Nigenda‐Morales, Éadin N. O'Mahony, Erika Oteri, Danai Papageorgiou, Kim M. Parsons, Nicolás Restrepo‐Garzón, Lennart Schreiber, Ramari Oliphant Stewart, David L. J. Vendrami, Morten Tange Olsen, Ebru Unal, Catherine E. Meyer, Sebastian Alvarez‐Costes   +32 more
wiley   +1 more source

Late-Onset Huntington's Disease: A Case Report and Literature Review. [PDF]

Cureus
Gonçalves C, Ferreira AS, Calheiros A, Lopes Freitas R, Cacao G.   +4 more
europepmc   +1 more source

Design, Synthesis, and Biological Evaluation of Pyrazolyl Thioureas (PTUs) as SIRT1 and SIRT2 Inhibitors

ChemMedChem, Volume 21, Issue 18, 28 September 2026.
Pyrazolyl thioureas were designed and synthesized as sirtuin 1 (SIRT1) and sirtuin 2 (SIRT2) inhibitors. 6a (IC50 (SIRT1) = 5.3 µM; IC50 (SIRT2) = 2.2 µM) and 7f (IC50 (SIRT1) = 12.4 µM; IC50 (SIRT2) = 13.6 µM) showed micromolar inhibition on target enzymes and HepG2‐based assays confirmed a SIRT2‐mediated effect on tubulin acetylation. Docking studies
Matteo Lusardi, Cecilia Astigiano, Deianira Bellitto, Matteo Raineri, Giorgia Guccione, Annalisa Salis, Elena Cichero, Chiara Brullo, Marco Ponassi, Santina Bruzzone, Andrea Spallarossa   +10 more
wiley   +1 more source

Treatment of Huntington's disease with a pan-HTT-targeting CRISPR nuclease. [PDF]

Mol Ther
Tan K, Del Bosque Siller D, Xiong AY, Wang AXA, McCallister TX, Mummadi S, St John LA, Lee TK, Carrillo AN, Renshaw DG, Zhou RH, Lim CKW, He J, Fields CJ, Hayden MR, Gaj T.   +15 more
europepmc   +1 more source

Significant underascertainment in Huntington's disease. [PDF]

Brain Commun
Lee S, Weisburd B, Lee J, Correia K, Zeng S, Park SS, Shin JW, Choi DE, Kim KH, Jang JH, Gillis T, Rehm HL, Gusella JF, MacDonald ME, Lee JM.   +14 more
europepmc   +1 more source

Stage-dependent tau-PET signatures in Huntington's disease revealed by [¹⁸F]PI-2620. [PDF]

Eur J Nucl Med Mol Imaging
Martinez-Horta S, Perez-Perez J, Puig-Davi A, Camacho V, Perez-Carasol L, Franch-Marti C, Olmedo-Saura G, Fernandez-Leon A, Flotats A, Kolinger GD, Bullich S, Perez-Martinez E, Pagonabarraga J, Kulisevsky J.   +13 more
europepmc   +1 more source

HD-DRUM rhythmic training in Huntington’s disease: feasibility, motor, and brain microstructural pilot signals

Laguna PL, Ioakeimidis V, Drew CJG, Pallmann P, Busse-Morris M, Watson GB, Schubert R, Rosser AE, Metzler-Baddeley C.   +8 more
europepmc   +1 more source

Longitudinal trajectories of apathy in Huntington's disease: a 6-year follow-up study. [PDF]

J Neurol
Poulsen E, Hendel RK, Ásbjörnsdóttir B, Hjermind LE, Nielsen JE, Vogel A.   +5 more
europepmc   +1 more source

Network-based stratification of allele-specific expression reveals patient subgroups in Huntington's disease. [PDF]

Bioinformatics
van Beek D, Iyer A, Ehrhart F, Evelo CT, de Kok TM, Arts ICW, Adriaens ME, Kutmon M.   +7 more
europepmc   +1 more source